ClinicalTrials.gg

Program

PRMT5 Inhibitor BGB-58067

Also written as “BGB-58067”, “BGB-58067 Tablet (F-01 Formulation)” and “BGB-58067 Tablet (F-02 Formulation)”.

Its studies are led by BeOne Medicines.

Furthest: phase 1, since Sep 6, 20242 company-led studies, 2 open or runningNext primary completion: Jul 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines22 open or runningphase 1since Sep 6, 2024Sep 6, 2024Jul 1, 2027phase 1 · NCT07712640

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06589596 · 695 planned · United States, Australia, Brazil and more
  2. Jul 9, 2026Phase 1 study in Healthy VolunteersNCT07712640 · 32 planned · Australia
  3. Oct 20, 2026Primary completion moved from 2027-09-30 to 2028-08-31Date moved laterphase 1 · +11 months · NCT06589596

Ahead

  1. Jul 1, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07712640
  2. Aug 31, 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06589596

TargetBeta

PRMT5 →read by rule
“A methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07712640Healthy Volunteers · Australia1RecruitingJul 1, 202732
NCT06589596Advanced Solid Tumor · United States, Australia, Brazil and more1RecruitingAug 31, 2028695

How it is read

Names in the registry

  • “BGB-58067”, 1 entry
  • “BGB-58067 Tablet (F-01 Formulation)”, 1 entry
  • “BGB-58067 Tablet (F-02 Formulation)”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.